Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. - Wikidata - wikimedia - TriplyDB

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

http://www.wikidata.org/entity/Q34130128

about

Kallikreins as biomarkers for prostate cancer Prostate cancer screening in Brazil: should it be done or not?Early detection of prostate cancer: AUA Guideline.Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0.Prostate-specific antigen screening in prostate cancer: perspectives on the evidence Prevention and early detection of prostate cancer.Expected population impacts of discontinued prostate-specific antigen screening.Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(₁₄₅) or Lys(₁₄₆) from fPSA without internal cleavages at Lys(₁₄₅) or Lys(₁₄₆).Identification of a novel proteoform of prostate specific antigen (SNP-L132I) in clinical samples by multiple reaction monitoring Serum markers in prostate cancer detection Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer.Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.The Lake Wobegon Effect: Why Most Patients Are at Below-Average Risk Evaluation of a rapid quantitative determination method of PSA concentration with gold immunochromatographic strips.Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.Successful external validation of a model to predict other cause mortality in localized prostate cancer Identification of plasma protein profiles associated with risk groups of prostate cancer patients Matched case-control studies: a review of reported statistical methodology Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.Predicting prostate cancer many years before diagnosis: how and why?PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer.Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.Screening for prostate cancer: early detection or overdetection?A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort Overdiagnosis of prostate cancer.Genome-wide association study identifies loci at ATF7IP and KLK2 associated with percentage of circulating free PSA.Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations Tumor markers in prostate cancer I: blood-based markers.The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States.Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer Copy number variants in the kallikrein gene cluster.Age and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer.Biomarkers in prostate cancer surveillance and screening: past, present, and future.PSA mass screening: is there enough evidence?Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer.

P2860

Q26862434-5FD726F3-EEB6-4CB1-8D76-0AF502F9B726 Q28068688-86222E14-2200-4A75-968B-1952C7773C63 Q33608474-75D410EC-173E-491A-B150-C9C7000B75C6 Q33750148-CDDF8FFE-CF3F-44C5-8D67-45C0502A2BD9 Q33820579-42988AA9-0AE2-493C-97F5-C29CEFF4BEF9 Q34259095-64200188-2072-4FDA-B49D-D940A26B6C77 Q34354430-3D76FE08-2716-4546-A24E-F55D7039A3DC Q34371057-8B4FD0CF-9D91-4787-BC00-E6AB735A868F Q34458237-715DCD56-111C-4E52-8BCE-F5289FD9BBC5 Q34751961-7051AC09-E5C1-460A-96F7-0CFE5AF86F8B Q34810177-7738DBAE-8F7B-438C-855C-97CA767C3567 Q35042519-649E1954-D89C-4690-B7D3-C17486A77EC9 Q35089983-192AB286-299F-49F4-A35C-ABE2149EEF24 Q35110766-08DBE472-5063-4768-A043-B24478EF3D7B Q35718345-946CD352-FC92-4EEF-BBC2-FCD147387A45 Q35748486-3A07EA2D-03AC-4613-8B3D-5F86FDAC5000 Q35831125-BF376AA6-A497-4C4F-9B5A-2D351A4FA2A4 Q35832798-FACE4534-38C0-431F-A816-CFEB94C5DD4A Q35918818-38179924-3845-4D66-8A8E-8832AA68A09C Q35940183-6803BC4F-A125-474D-9BDA-1E80A230B8A1 Q35940220-F60BE922-29CF-43FC-9FC0-63B61783C4D1 Q35956405-01EC7D2D-83F9-4B9A-8031-BC4CC3A2B70F Q36026045-A8362FFF-52D4-4A18-9842-6E87E614AEF1 Q36033729-072698FA-B35D-4EA8-8886-79651423ECA9 Q36070376-2FE6EDAB-232D-42BF-B19D-0FCA3EAFC426 Q36145417-95DB954B-24AD-4CF7-BE95-751386B672EB Q36152421-ECFDC7A7-1BAD-4F1F-A5D6-1F5AAC8055CD Q36275998-6CF40E3C-B24A-4D53-AEBB-8D06592BCAFC Q36520508-E93FFE9C-D3BB-4ECB-91C1-659F86E4D77F Q36567585-E9CF5E63-F859-4D32-BE8D-76F301B5B0EC Q36590875-B3E8A63E-46AF-4D08-BFA8-0932FDF1E89B Q36607766-B3329004-C89F-4DF5-95DA-5D7C0617A474 Q36686892-3B8DE4F0-0C1D-42AE-99F6-9674B07359EC Q36928846-865AFC2E-F1ED-4595-8FE4-4DA1BE70C535 Q37033760-083430FF-0091-439A-AFC9-FCAA8884638E Q37043425-223263B8-35CF-497C-8526-32302B3D7DDD Q37300931-7561B7A8-2B5D-4A70-8C9D-5E7F410D0A70 Q37579100-E3A1FED7-03F6-4B6D-83AA-8B35ACDD48DE Q37600503-C66CC7A1-6E6B-4F8D-8C5C-0BA04CF60156 Q37622580-F9D615BB-6D19-4673-AF23-7429D99921EE

P2860

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

http://www.wikidata.org/entity/Q34130128

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Prostate specific antigen conc ...... te cancer: case-control study.

@ast

Prostate specific antigen conc ...... te cancer: case-control study.

@en

Prostate specific antigen conc ...... te cancer: case-control study.

@nl

type

label

Prostate specific antigen conc ...... te cancer: case-control study.

@ast

Prostate specific antigen conc ...... te cancer: case-control study.

@en

Prostate specific antigen conc ...... te cancer: case-control study.

@nl

prefLabel

Prostate specific antigen conc ...... te cancer: case-control study.

@ast

Prostate specific antigen conc ...... te cancer: case-control study.

@en

Prostate specific antigen conc ...... te cancer: case-control study.

@nl

P1433

Q34130128-838B9961-3DF0-4599-AA16-6731C77012B3

P1476

Q34130128-3C2222A6-B866-4BF0-8970-AAACA769BDFF

P2093

Q34130128-05828D66-AE80-473A-98B0-F2DD408DC13D

Q34130128-19701649-A52F-411D-9BF9-568DA6C19F98

Q34130128-5312B077-DD0B-4E76-AA0B-01CEA30A057F

Q34130128-5D498019-4FB1-43CD-ABAC-820E9B30487C

Q34130128-6562CEB3-A7EB-457E-BD99-1DE9379DF408

Q34130128-812E8BAF-31FA-464A-BBE5-C1BCD4F539E5

Q34130128-A6B0CDC8-3A6A-4021-A6BE-F3BD5072CBEA

P2860

Q34130128-02299ED3-F3A3-4556-ACA6-4AF487EA60E6

Q34130128-171FAA82-123D-449B-A56F-478AE5DD5E84

Q34130128-24D50129-9B18-4693-A603-A19C7CE1F0D3

Q34130128-3B78B8B3-5983-4D5B-B385-1E916D5764B8

Q34130128-3E2DF90A-761C-4B76-B786-4708BDF4689C

Q34130128-41E44FE2-F57F-4E87-A2C4-55AF8B79F979

Q34130128-4967E7CD-96AE-4D54-8E48-A6869B3908B3

Q34130128-56D73287-D128-4A98-A1DA-1B2C2F6CE777

Q34130128-5FA6E049-B65E-4510-A36E-EA02E363CDFA

Q34130128-6058FE32-FED7-4257-AB56-4AE1A51AB2D4

P304

Q34130128-26BA0656-08C2-41A5-AAD3-C2F81C3EF831

P31

Q34130128-38AAF55E-B29A-448A-9AE4-A03544661C4B

P356

Q34130128-7C2330C6-9F33-4984-B85B-9FCC15DB6C34

P407

Q34130128-DDCF870C-C0AE-4ADC-9350-2CACE2F7DBBB

P478

Q34130128-F5D0A00F-E328-42E8-97B4-8F95006325E5

P50

Q34130128-06AEF4D3-E59D-4845-A44D-82A78EC681A1

Q34130128-1A83B29F-D1EF-4C95-8384-937E32213808

Q34130128-316D0F93-DD75-418B-8C89-36BD85BB1C86

P577

Q34130128-C5E3E35C-D333-4635-BE32-C801EE3D49E0

P698

Q34130128-2BE23FCD-2610-414E-9F61-F17679022433

P932

Q34130128-E99582BF-8623-4083-8DD5-3E72632868C8

P356

P1433

P1476

Prostate specific antigen conc ...... ate cancer: case-control study

@en

P2093

Anders Bjartell

http://www.w3.org/2001/XMLSchema#string

Anders Dahlin

http://www.w3.org/2001/XMLSchema#string

Angel M Cronin

http://www.w3.org/2001/XMLSchema#string

Jonas Manjer

http://www.w3.org/2001/XMLSchema#string

Peter M Nilsson

http://www.w3.org/2001/XMLSchema#string

Peter T Scardino

http://www.w3.org/2001/XMLSchema#string

Thomas Björk

http://www.w3.org/2001/XMLSchema#string

P2860

Mortality results from a randomized prostate-cancer screening trial

Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005

Prostate-Cancer Screening

Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach

Screening and prostate-cancer mortality in a randomized European study

Effect of dutasteride on the risk of prostate cancer.

Estimating the empirical Lorenz curve and Gini coefficient in the presence of error with nested data.

Validity of a population-based cancer register in Sweden--an assessment of data reproducibility in the South-East Region Prostate Cancer Register.

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study

The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review.

P304

c4521

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.C4521

http://www.w3.org/2001/XMLSchema#string

P407

P478

341

http://www.w3.org/2001/XMLSchema#string

P50

Andrew J Vickers

P577

2010-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20843935

http://www.w3.org/2001/XMLSchema#string

P932

2939950

http://www.w3.org/2001/XMLSchema#string